Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$4.4B
163M shares
52-week range
$18.77 – $30.42
71% from low
Sector
DENTAL EQUIPMENT & SUPPLIES
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.84B | $2.28B | $1.93B | $2.51B | $2.57B | $2.57B | $2.51B | $2.72B |
| Cost of revenue | $1.23B | $933.1M | $856.0M | $1.05B | $1.08B | $1.12B | $1.12B | $1.22B |
| Gross profit | $1.61B | $1.35B | $1.07B | $1.46B | $1.49B | $1.45B | $1.39B | $1.50B |
| Gross margin | 56.6% | 59.2% | 55.6% | 58.3% | 57.9% | 56.5% | 55.4% | 55.0% |
| R&D | $172.0M | $133.1M | $86.7M | $100.5M | $100.1M | $93.8M | $99.1M | $114.0M |
| Operating income | $298.4M | $235.7M | $43.5M | $306.2M | $319.2M | $31.5M | −$1.04B | $225.7M |
| EBITDA | $454.8M | $377.0M | $260.2M | $496.0M | $497.7M | $463.0M | $279.5M | $329.8M |
| Net income | $230.7M | $217.6M | $33.3M | $340.5M | $243.1M | −$100.2M | −$1.12B | $47.0M |
| Net margin | 8.1% | 9.5% | 1.7% | 13.6% | 9.5% | -3.9% | -44.6% | 1.7% |
| EPS (diluted) | 1.80 | 1.35 | 0.26 | 1.48 | 1.34 | -0.60 | -6.50 | 0.28 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.9B | $1.43 | $1.40–$1.46 | 10 |
| 2027 | $3.0B | $1.57 | $1.54–$1.60 | 10 |
| 2028 | $3.1B | $1.72 | $1.20–$2.00 | 4 |
| 2029 | $3.2B | $1.91 | $1.88–$1.94 | 2 |
Forward consensus · source: Financial Modeling Prep
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
www.envistaco.comNo one on the platform currently holds NVST.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,208,165 | $30.7M |
| Bridgewater Associatesas of 2026-03-31 | 76,437 | $1.9M |
| Execution date | Ratio |
|---|---|
| 2008-08-19 | 1-for-10reverse |
| 2006-01-12 | 1-for-300reverse |
No one on the platform has traded NVST yet.
| $3.5B |
| — |
| GRALGRAIL Inc. | $68.39 | +3.75% | $2.9B | — |
| ICUIICU Medical, Inc. | $147.93 | -0.23% | $3.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at NaN× earnings vs its 29.9× historical median P/E.
Fair value ≈ $-195.21 · price $27.02 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$NVST Share Price: $25.90 Contract Selected: Dec 18, 2026 $25 Calls Buy Zone: $3.06 – $3.78 Target Zone: $4.90 – $5.98 Potential Upside: 51% ROI Time to Expiration: 182 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗10X POTENTIAL 🔥🚨 $NVST 30 CALL 7/17 avg .30🚨
View on StockTwits ↗https://marketbeat.com/a/8651703/ $NVST Envista Q1 Earnings Call Highlights
View on StockTwits ↗$NVST Biopharmaceutical companies are entering an aggressive acquisition and R&D investment cycle to expand therapeutic portfolios and accelerate pipeline development, accepting near-term earnings pressure for long-term growth. Learn more: https://axlfi.com/themes/220
View on StockTwits ↗$DASH $EZPW $NVST $PTC $ORA AFTER-HOURS MOVERS: Currently Higher After Earnings: - Noodles & Company (NDLS) up 21.1% - Fortinet (FTNT) up 15.9% - Kulicke and Soffa Industries (KLIC) up 15.4% - Cognex (CGNX) up 14.0% - Array Technologies (ARRY) up 11.3% - DoorDash (DASH) up 10.8% - EZCORP (EZPW) up 9.9% - Envista Holdings (NVST) up 6.8% - PTC Inc. (PTC) up 7.6% - Ormat Technologies (ORA) up 6.6% - AppLovin (APP) up 0.4% Currently Lower After Earnings: - Fastly (FSLY) down 25.3% - Whirlpool (WHR) down 16.4% - Tutor Perini (TPC) down 9.7% - Core Scientific (CORZ) down 8.0% - Amprius Technologies (AMPX) down 8.4% - Snap (SNAP) down 9.5% - Coherent (COHR) down 7.2% - Arm (ARM) down 6.4% - IonQ (IONQ) down 6.2% - Zillow (ZG) down 5.8% .
View on StockTwits ↗$NVST Q1 '26 Earnings Results & Recap Reported GAAP EPS of $0.24 up 140.00% YoY
View on StockTwits ↗$MVST Just klicked accidentally the $NVST ticker and thought the day was already here. Well but soon we will be there.
View on StockTwits ↗Wall St is expecting 0.31 EPS for $NVST Q1 [Reporting 05/06 AMC] http://www.estimize.com/intro/nvst?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$NVST Envista has strong brands in an attractive long-term market (aging population = more dental work), but they're facing a perfect storm of high debt, margin pressure, and execution risk. The company needs a near-perfect turnaround to justify current valuations. For most investors, there are probably better places to put your money while you wait to see if management can pull this off. https://stratafinance.beehiiv.com/p/envista
View on StockTwits ↗$NVST I decided to pass on NVST because the pullback has too many Red Bricks. The sweet spot is a 2 or 3 Red Brick pullback.
View on StockTwits ↗$NVST 195 MIN and Weekly 1% Renko charts I'll take a 1/2 position on Monday if the price is still above 29.
View on StockTwits ↗$AMPX $INTC $NVST $AMPX To understand why Atomera is so "wonderful" in the eyes of engineers, you have to look at the physics. While the industry has used "Strained Silicon" for 20 years, Atomera’s MST is a fundamentally different—and harder to replicate—beast. The Technical Edge: MST vs. Strained Silicon For decades, the industry used Strained Silicon to speed up chips. This involves physically "stretching" or "compressing" the silicon atoms to let electrons flow faster. However, as chips get smaller, Strained Silicon reaches a physical limit—it’s like trying to stretch a rubber band that is already at its breaking point. MST (Mears Silicon Technology) takes a different approach called Oxygen Insertion: * The "Traffic Light" Effect: Instead of stretching the silicon, MST inserts layers of individual oxygen atoms. These layers act like traffic directors, smoothing the path for electrons (reducing "scattering") and blocking unwanted chemical "leaks" (dopant diffusion). * The Diffusion Barrier: In modern chips, different chemicals (dopants) tend to "bleed" into areas where they don't belong, causing errors. MST acts like a microscopic dam, keeping these chemicals exactly where they are supposed to be. * Layering Advantage: Unlike Strained Silicon, which is usually a one-time treatment, MST can be layered multiple times within a single transistor to stack the benefits. Why It Is Hard to Copy Atomera’s "moat" isn't just a single patent; it’s a combination of 300+ patents and something even more valuable: Trade Secrets. * The "Recipe" Problem: While the idea of oxygen insertion is public, the "recipe" (the exact temperature, pressure, and gas flow needed to put those oxygen atoms in place without ruining the crystal) is a closely guarded secret. * Quantum Engineering: At these scales, you are dealing with quantum mechanics. If the oxygen atoms aren't placed with atomic precision, the whole chip fails. * The Equipment Moat: Atomera works directly with the major companies that build the machines (EPI tools) used in fabs. If a competitor wanted to copy MST, they would likely need to re-engineer the multi-million dollar machines themselves. The "Successful Future": What Does the Win Look Like? If we fast-forward to a successful 2030 for Atomera, the world looks quite different for them: * The "Atomera Inside" Era: Much like "Intel Inside" or "Dolby Vision," MST becomes a standard line item in chip design. When Apple or Nvidia designs a 1nm chip, MST is simply part of the base material specification. * Automotive Dominance: Because MST makes power-management chips more efficient, it becomes the gold standard for Electric Vehicles (EVs), extending range by 5-10% purely through material efficiency. * The Royalty Machine: Atomera transitions from a "struggling R&D firm" to a high-margin licensing powerhouse. Once MST is integrated into a "High Volume Manufacturing" (HVM) line, the revenue becomes passive. For every wafer a fab like TSMC or Samsung spins, Atomera collects a royalty check. Summary of Recent High-Value Movement (2018-2026) | Phase | Key Value Driver | Impact | |---|---|---| | Early (2018-2020) | Validation | Proved MST works in real-world "Foundry" environments. | | Mid (2021-2024) | Scalability | Strategic deal with STMicroelectronics and proving MST works on GaN (Gallium Nitride). | | Current (2025-2026) | Commercialization | Entering the "Royalty Phase" where the first mass-produced chips using MST hit the market. |
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.